Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Operating Leases: 2022-2024

Historic Operating Leases for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $51.6 million.

  • Entrada Therapeutics' Operating Leases fell 10.31% to $48.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.0 million, marking a year-over-year decrease of 10.31%. This contributed to the annual value of $51.6 million for FY2024, which is 14.38% down from last year.
  • As of FY2024, Entrada Therapeutics' Operating Leases stood at $51.6 million, which was down 14.38% from $60.3 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Operating Leases registered a high of $60.3 million during FY2023, and its lowest value of $17.5 million during FY2022.
  • Its 3-year average for Operating Leases is $43.2 million, with a median of $51.6 million in 2024.
  • As far as peak fluctuations go, Entrada Therapeutics' Operating Leases skyrocketed by 244.10% in 2023, and later declined by 14.38% in 2024.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Operating Leases stood at $17.5 million in 2022, then surged by 244.10% to $60.3 million in 2023, then dropped by 14.38% to $51.6 million in 2024.